Document is current

Article History

Received: 20 February 2022

Accepted: 11 October 2022

First Online: 15 November 2022

Declarations

:

: All human tissue obtained for PDX generation was from patients with a diagnosis of DPM who gave informed consent on an IRB-approved protocol at Memorial Sloan Kettering Cancer Center (MSK; 06-107 and/or 12-245). All animal experiments were approved by the Memorial Sloan Kettering Cancer Center (MSK; 14-091) Animal Care and Use Committee and mice were housed in accredited facilities under pathogen-free conditions. All study procedures were conducted in accordance with the US Common Rule which is an ethical standard established for conduct of any US government-funded research and conformed to the principles of the Helsinki Declaration.

: Not applicable.

: MDO has consulted regarding oncology drug development with Novartis, Jazz, and PharmaMar. MDO has received honorarium from Targeted Oncology, OncLive, and the American Society for Radiation Oncology.AR has consulted regarding oncology drug development with AstraZeneca, Merck, Boehringer Ingelheim, and Cybrexa. AR has received honorarium from MoreHealth and ResearchToPractice. AR serves on the scientific advisory boards of Merck. AR has received grants from Varian Medical Systems, Boehringer Ingelheim, Pfizer, AstraZeneca, and Merck.PSA has intellectual property and licensing royalties on mesothelin-targeted CAR T cell therapy, serves on scientific boards of Atara Bio, Bayer, BioArdis, Carisma therapeutics, Immugene, ImmPACT bio; consulted for Atara, Bayer; and has received research support from Atara BioMGZ has received consulting fees from Ikena, Takeda, GlaxoSmithKline, Aldeyra Therapeutics, and Novocure and honoraria for CME content from PER, Medscape, Research to Practice, Medical Learning Institute and OncLive. Memorial Sloan Kettering receives research funding from the Department of Defense, the National Institutes of Health, Precog, GlaxoSmithKline, Epizyme, Polaris, Sellas Life Sciences, Bristol Myers Squibb, Millenium/Takeda, Curis, and Atara for research conducted by MGZ. MGZ serves as Chair of the Board of Directors of the Mesothelioma Applied Research Foundation, an uncompensated position.CMR has consulted regarding oncology drug development with Amgen, Daiichi Sankyo, Genentech/Roche, Ipsen, Jazz, Merck, Pfizer, Syros, and Vavotek. CMR serves on the scientific advisory boards of Bridge Medicines, Earli, and Harpoon Therapeutics.TS has research funding from Jazz Pharmaceuticals.The remaining authors declare that they have no competing interests.